

GLENN W. KAATZ, M.D.

OFFICE ADDRESS

Division of Infectious Diseases
B4333 John D. Dingell VA Medical Center
4646 John R
Detroit, Michigan 48201 USA

OFFICE TELEPHONE: (313) 576-4491

EDUCATION

1972 - 1976 BS Degree, (graduated with high distinction with major in zoology), University of Michigan, Ann Arbor, MI

1976 - 1980 MD Degree, (graduated with distinction), University of Michigan, Ann Arbor, MI

TRAINING

1980 - 1981 Internship in Internal Medicine, University of Michigan Hospitals, Ann Arbor, MI

1981 - 1983 Residency in Internal Medicine, University of Michigan Hospitals, Ann Arbor, MI

1983 - 1986 Fellowship in Infectious Diseases, University of Michigan Hospitals, Ann Arbor, MI

FACULTY APPOINTMENTS

1986 - 1993 Assistant Professor of Medicine, Wayne State University School of Medicine, Detroit, MI

1991 - 1999 Adjunct Assistant Professor, College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, MI

1993 - 2002 Associate Professor of Medicine, Wayne State University School of Medicine, Detroit, MI

1999 – present Adjunct Associate Professor, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI

2000 Granted 25% tenure, Wayne State University, Detroit, MI

2002 – present Professor of Medicine, Wayne State University School of Medicine, Detroit, MI

HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS

1983 - 1984 Infection Control Committee, University of Michigan Medical Center, Ann Arbor, MI

1987 - 1988 Housestaff coordinator, Hutzel Hospital, Wayne State University School of Medicine, Detroit, MI

1987 - 1989 Residency Operations Committee, Wayne State University School of Medicine, Detroit, MI

Glenn W. Kaatz, M.D.
Curriculum Vitae
Page Two

- 1988 - 1989 Patient Care Committee, Harper Hospital, Detroit, MI
- 1988 - 1997 Infection Control Committee, Detroit Receiving Hospital, Detroit, MI
- 1988 - 1997 Pharmacy and Therapeutics Committee, Detroit Receiving Hospital, Detroit, MI
- 1995 - 2003 Human Investigation Committee, Wayne State University. Appointed Vice-Chair of MP-4 subcommittee, September 2000.
- 2001 - 2004 VA Research and Development Committee
- 2004-present Member, VA Clinical Investigation Committee (advanced to Chair January 2006)**
- 2005-present Member, Department of Medicine Research Steering Committee**
- 2005-2006 Member, Endocrinology and Metabolism Chair Search Committee**
- 2005-2006 Member, Biochemistry and Molecular Biology Search Committee for new faculty interested in studying aspects of the structural biology of infectious diseases**
- 2005-2006 Member, Graduate Program Enhancement Award Committee, charged with designing coursework to establish an interdisciplinary Graduate program including the Departments of Immunology/Microbiology, Biochemistry and Molecular Biology, and Medicine, Division of Infectious Diseases**

PROFESSIONAL SOCIETIES

American Society for Microbiology
British Society for Antimicrobial Chemotherapy
Infectious Disease Society of America (elected to Fellow status, 1996)

LICENSURE & BOARD CERTIFICATION

Licensure - State of Michigan (license number 43964)

1981 - National Board of Medical Examiners
1983 - American Board of Internal Medicine (certification number 94372)
1988 - Subspecialty certification in Infectious Diseases (certification number 94372)

HONORS AND AWARDS

1971 - National Honor Society (High School)
1972 - Phi Beta Kappa (High School)
1972 - William Branstrom Freshman Prize (*University of Michigan*)
1972 - Phi Eta Sigma Freshman Honor Fraternity (*University of Michigan*)
1974 - Phillips Classical Prize (*University of Michigan*)
1976 - Phi Beta Kappa
1980 - Alpha Omega Alpha Medical Honor Society
1990 - Upjohn Laboratories Award for Excellence in Infectious Disease Research, Midwest Section, AFCR
2006 – Wayne State University School of Medicine Teaching Award

SERVICE

1. Patient care: 4 months/year inpatient work, one-half day per week outpatient clinic
2. Professional consultation: expert witness in legal matters no more than once per year
3. Journal/editorial activity
 - a. Review 10-15 manuscripts/year for peer-reviewed journals
 - b. Member of editorial board, *Expert Opinion on Emerging Drugs* (2001 – present)
 - c. **Member of editorial board, *Journal of Medical Microbiology* (2006 – present)**
4. Other professionally related service: none
5. National and international boards and committees: none
6. State and local boards and committees: none

TEACHING

1. Years at Wayne State: 21
2. Years at other colleges/universities: none
3. Courses taught at Wayne State in last five years
 - a. Pharmacy students: clinical correlations of microbiologic data (1-2 times yearly).
 - b. Medical students: physical diagnosis (5-6 sessions per year)
 - c. Medical students/Residents: Hospital-based general medicine (1-2 months per year clinical rounding)
 - d. Medical students/Residents/Fellows: Hospital- and outpatient-based infectious diseases (3 months per year clinical rounding in hospital, year-around in outpatient and laboratory settings)
4. Essays/Theses/Dissertations directed: none
5. Course or curriculum development: none
6. Course materials: none
7. Infectious Diseases Fellows trained in the laboratory: Nancy Dorman, MD (1989-90), Cheryl Ruble, MD (1990-91), Tammy Lundstrom, MD (1991-92), Cesar Randich, MD (1994-95), George Varghese, MD (1996-97), Mettesabia Kanno (1998-99), Mohammad Wahiduzzaman, MD (1999-2000), Salvadore Abad-Santos, MD (2000-01), Varsha Moudgal, MD (2002-03), **Rama Thyagarajan, MD (2004-05), Carmen DeMarco, MD (2005-07), Laurel Cushing, MD (2006-07), Emmanuel Frempong-Manso (2007-08).**
8. **Undergraduate students mentored in the laboratory: Mashkur Husain (2005-06), Shawn Francis (2006), Eric Strother (2006-07).**

STUDY SECTIONS

1997-1998, 2000	NIH-Oral Biology and Medicine I (ad-hoc reviewer)
1998-1999	VA-Merit Review (ad-hoc reviewer-Infectious Diseases) NIH/NIAID-Special Emphasis Panel for RFP-NIH-NIAID-DMID-98-24, Network on Antimicrobial Resistance in <i>Staphylococcus aureus</i>
1999	NIH/NIDR Special Emphasis Panel for R01 DE 13559-01, Impact of Amoxicillin on Bacteremia from Oral pathogens (ad-hoc reviewer)
2000, 2005	The Wellcome Trust (ad-hoc reviewer)
2002	National Science Foundation, Microbial Genetics section (ad-hoc reviewer) NIH-Bacteriology and Mycology I (ad-hoc reviewer)
2004	British Society for Antimicrobial Chemotherapy (ad-hoc reviewer)
2005	Natural Sciences and Engineering Research Council of Canada (NSERC) (ad-hoc reviewer)
2006	NIH/NIAID-Special Emphasis Panel for RFP-NIH-NIAID-DMID-07-11, Network on Antimicrobial Resistance in <i>Staphylococcus aureus</i> (NARSA)

GRANT SUPPORT

1987 - 1988	"Mechanism of ciprofloxacin resistance in <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> ." PI, funded by FMRE, WSU, \$25,000.
1988 - 1989	"Comparative efficacy of ciprofloxacin, rifampin, ciprofloxacin plus rifampin, and vancomycin in the therapy of experimental <i>Staphylococcus aureus</i> endocarditis in rabbits." PI, funded by Miles Pharmaceuticals, \$32,000. "Comparative efficacy of fleroxacin and vancomycin in the therapy of experimental <i>Staphylococcus aureus</i> endocarditis in rabbits." PI, funded by Hoffman-La Roche, Inc., \$48,000. "The treatment with ofloxacin of experimental <i>Staphylococcus aureus</i> endocarditis in rabbits." PI, funded by Ortho Pharmaceutical Corp., \$54,000.
1989 - 1990	"Comparative efficacies of daptomycin, teicoplanin, and vancomycin in the therapy of experimental <i>Staphylococcus aureus</i> endocarditis in rabbits." PI, funded by Eli Lilly and Company, \$59,000. "In-vitro evaluation of WIN 57273, a new quinolone antimicrobial agent." PI, funded by Sterling-Winthrop, Inc., \$24,000. "Mechanism of teicoplanin resistance in <i>Staphylococcus aureus</i> ." PI, funded by Merrell-Dow Research Institute, \$13,000.

- 1990 - 1991 "Comparative efficacies of CI-960 and vancomycin in experimental *Staphylococcus aureus* endocarditis." PI, funded by Parke-Davis Pharmaceutical Research, \$49,000.
- 1991 - 1992 "Mechanism of daptomycin resistance in *Staphylococcus aureus*." PI, funded by Eli Lilly and Company, \$46,000.
- 1992 - 1993 "Mechanisms of fluoroquinolone resistance in *Staphylococcus aureus*." PI, funded by Parke-Davis Pharmaceutical Research, \$10,000.
- 1993 - 1996 "In vitro pharmacodynamic model of infective endocarditis." Co-PI (Rybak M, B McGrath, L Kang, and G Kaatz), funded by Proctor and Gamble Animal Alternatives Research Program, \$150,000.
- 1995 "In vitro activity of oxazolidinones versus methicillin-susceptible and -resistant staphylococci." PI, funded by Upjohn Company, \$15,840.
- 1996 - 1997 "Comparative efficacy of LY333328 and vancomycin in the therapy of experimental methicillin-resistant *Staphylococcus aureus* endocarditis in rabbits." PI, funded by Eli Lilly and Company, \$43,000.
- "Comparative efficacy of trovafloxacin and vancomycin in the therapy of experimental *Staphylococcus aureus* endocarditis in rabbits." PI, funded by Pfizer Inc., \$52,000.
- 1997 - 1998 "Molecular basis of clinafloxacin advantage." PI, funded by Parke-Davis Pharmaceutical Research, \$29,000.
- 1997 - 2000 "Efflux-related Multidrug Resistance in *Staphylococcus aureus*." PI, funded by the VA Merit Review for 3 years, \$204,500.
- 2000 - 2001 "Efflux-mediated resistance to moxifloxacin." PI, funded by Bayer Corp., \$34,100.
- 2001 – 2005 "Efflux-related Multidrug Resistance in *Staphylococcus aureus*." PI, funded by the VA Merit Review (renewal) for 4 years, \$367,000.
- 2002 – 2003 "Transfer of a daptomycin-resistance phenotype to a susceptible strain of *Staphylococcus aureus* by phage transduction." PI, funded by Cubist Pharmaceuticals, \$2,000.
- 2005 – 2006 "Fluoroquinolone Resistance Mechanisms in *Pseudomonas aeruginosa*." PI, funded by Ortho-McNeil Pharmaceuticals, \$8,000.**
- 2005 – 2009 "MepA, a Novel MATE-Family Multidrug Efflux Pump in *Staphylococcus aureus*." PI, funded by the VA Merit Review for 4 years (\$484,800).**
- 2007 – 2008 "Mechanisms of daptomycin nonsusceptibility in *Staphylococcus aureus*." PI, funded by Cubist Pharmaceuticals, \$34,000.**

PUBLICATIONS

Original observations in refereed journals

1. **Kaatz G**, S Barriere, D Schaberg, and R Fekety: Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* 31:527-30, 1987.
2. Barriere S, **G Kaatz**, D Schaberg, and R Fekety: Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits. *Antimicrob Agents Chemother* 31:1075-78, 1987.
3. **Kaatz G**, S Barriere, D Schaberg, and R Fekety: The emergence of resistance to ciprofloxacin during therapy of experimental methicillin-susceptible *Staphylococcus aureus* endocarditis. *J Antimicrob Chemother* 20:753-58, 1987.
4. **Kaatz G**, S Gitlin, D Schaberg, K Wilson, C Kauffman, S Seo, and R Fekety: Acquisition of *Clostridium difficile* from the hospital environment. *Am J Epidemiol* 127:1289-94, 1988.
5. **Kaatz G**, and S Seo: Mechanism of ciprofloxacin resistance in *Pseudomonas aeruginosa*. *J Infect Dis* 158:537-41, 1988.
6. **Kaatz G**, S Seo, S Barriere, L Albrecht, and M Rybak: Efficacy of fleroxacin in experimental methicillin-resistant *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* 33:519-21, 1989.
7. Barriere S, **G Kaatz**, and S Seo: Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits. *Antimicrob Agents Chemother* 33:589-90, 1989.
8. **Kaatz G**, S Seo, S Barriere, L Albrecht, and M Rybak: Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* 33:1184-87, 1989.
9. **Kaatz G**, S Seo, S Barriere, L Albrecht, and M Rybak: Efficacy of ofloxacin in experimental *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* 34:257-60, 1990.
10. **Kaatz G**, S Seo, N Dorman, and S Lerner: Emergence of teicoplanin resistance during therapy of *Staphylococcus aureus* endocarditis. *J Infect Dis* 162:103-108, 1990.
11. **Kaatz G**, and S Seo: WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens. *Antimicrob Agents Chemother* 34:1376-80, 1990.
12. **Kaatz G**, S Seo, V Reddy, E Bailey, and M Rybak: Daptomycin compared with teicoplanin and vancomycin for therapy of experimental *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* 34:2081-85, 1990.
13. **Kaatz G**, S Seo, and C Ruble: Mechanisms of fluoroquinolone resistance in *Staphylococcus aureus*. *J Infect Dis* 163:1080-86, 1991.
14. Bailey E, M Rybak, and **G Kaatz**: Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. *Antimicrob Agents Chemother* 35:1089-1092, 1991.

15. **Kaatz G**, S Seo, S Barriere, L Albrecht, and M Rybak: Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible *Staphylococcus aureus* endocarditis. Antimicrob Agents Chemother 35:1547-1550, 1991.
16. Rybak M, E Bailey, K Lamp, and **G Kaatz**: Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother 36:1109-1114, 1992.
17. **Kaatz G**, S Seo, K Lamp, E Bailey, and M Rybak: CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant *Staphylococcus aureus* endocarditis. Antimicrob Agents Chemother 36:1192-1197, 1992.
18. Lamp K, M Rybak, E Bailey, and **G Kaatz**: In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 36:2709-2714, 1992.
19. Neyfakh A, C Borsch, and **G Kaatz**: Fluoroquinolone resistance protein *NorA* of *Staphylococcus aureus* is a multidrug efflux transporter. Antimicrob Agents Chemother 37:128-129, 1993.
20. Thal L, J Vazquez, M Perri, A Beckley, S Donabedian, **G Kaatz**, J Patterson, and M Zervos: Activity of ampicillin plus sulbactam against β -lactamase producing enterococci in experimental endocarditis. J Antimicrob Chemother 31:182-185, 1993.
21. **Kaatz G**, S Seo, and C Ruble: Efflux-mediated fluoroquinolone resistance in *Staphylococcus aureus*. Antimicrob Agents Chemother 37:1086-1094, 1993.
22. McGrath B, Kang SL, **Kaatz G**, and M Rybak: Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against *Staphylococcus aureus* in an in vitro pharmacodynamic model of endocarditis. Antimicrob Agents Chemother 38:2034-2040, 1994.
23. Kang S, Rybak M, McGrath B, **Kaatz G**, and S Seo: Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant *Staphylococcus aureus* in an in vitro infection model. Antimicrob Agents Chemother 38:2702-2709, 1994.
24. Zabinski R, Walker K, Larsson A, Moody J, **Kaatz G**, and J Roschafer: Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones. Antimicrob Agents Chemother 39:507-512, 1995.
25. **Kaatz G**, and S Seo: Inducible *NorA*-mediated multidrug resistance in *Staphylococcus aureus*. Antimicrob Agents Chemother 39:2650-2655, 1995.
26. **Kaatz G**, and S Seo: In vitro activity of oxazolidinone compounds U100592 and U100766 against *Staphylococcus aureus* and *Staphylococcus epidermidis*. Antimicrob Agents Chemother 40:799-801, 1996.
27. Rybak M, H Houlihan, R Mercier, and **G Kaatz**: Pharmacodynamics of RP 59500 (quinupristin/dalfopristin) administered by intermittent versus continuous infusion against *Staphylococcus aureus*-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother 41:1359-1363, 1997.

28. **Kaatz G**, and S Seo: Mechanisms of fluoroquinolone resistance in genetically-related strains of *Staphylococcus aureus*. *Antimicrob Agents Chemother* 41:2733-2737, 1997.
29. **Kaatz G**, and S Seo: Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of *Staphylococcus aureus*. *Antimicrob Agents Chemother* 42:197-198, 1998.
30. **Kaatz G**, S Seo, J Aeschlimann, H Houlihan, R Mercier, and M Rybak: Efficacy of trovafloxacin against experimental *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* 42:254-256, 1998.
31. Rybak M, D Cappelletty, T Moldovan, J Aeschlimann, and **G Kaatz**: Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against *Staphylococcus aureus*, coagulase-negative staphylococci, *Enterococcus faecalis* and *Enterococcus faecium*. *Antimicrob Agents Chemother* 42:721-724, 1998.
32. **Kaatz G**, S Seo, J Aeschlimann, H Houlihan, R Mercier, and M Rybak: Efficacy of LY333328 against experimental methicillin-resistant *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* 42:981-983, 1998.
33. Shimada K, A Saito, K Yamaguchi, T Inamatsu, Y Kobayashi, T Oguma, **G Kaatz**, M Rybak, J Boyce, M Zeckel, and H Murao: The 3rd Japanese-United States vancomycin forum. *Jpn J Antibiot* 51:363-394, 1998.
34. Aeschlimann J, L Dresser, **G Kaatz**, and M Rybak: Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of *Staphylococcus aureus*. *Antimicrob Agents Chemother* 43:335-340, 1999.
35. Aeschlimann J, **G Kaatz**, and M Rybak: The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of *Staphylococcus aureus* in an in-vitro infection model. *J Antimicrob Chemother* 44:343-349, 1999.
36. **Kaatz G**, S Seo, and T Foster: Introduction of a *norA* promoter-region mutation into the chromosome of a fluoroquinolone-susceptible strain of *Staphylococcus aureus* using plasmid integration. *Antimicrob Agents Chemother* 43:2222-2224, 1999.
37. **Kaatz G**, S Seo, L O'Brien, M Wahiduzzaman, and T Foster: Evidence for the existence of a multidrug efflux transporter distinct from NorA in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 44:1404-1406, 2000.
38. Hershberger E, E Coyle, **G Kaatz**, M Zervos, and M Rybak: Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations. *Antimicrob Agents Chemother* 44:1921-1924, 2000.
39. Coyle E, **G Kaatz**, and M Rybak: Activities of newer fluoroquinolones against ciprofloxacin-resistant *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 45:1654-1659, 2001.
40. Price C, **G Kaatz**, and J Gustafson: The multidrug efflux pump NorA is not required for salicylate-induced reduction in drug accumulation by *Staphylococcus aureus*. *Int J Antimicrob Agents* 20:206-213, 2002.

41. **Kaatz G**, V Moudgal, and S Seo: Identification and characterization of a novel efflux-related multidrug resistance phenotype in *Staphylococcus aureus*. *J Antimicrob Chemother* 50:833-838, 2002.
42. Gibbons S, M Oluwatuyi, and **G Kaatz**: A novel inhibitor of multidrug efflux pumps in *Staphylococcus aureus*. *J Antimicrob Chemother* 51:13-17, 2003.
43. **Kaatz G**, V Moudgal, S Seo, and J Kristiansen: Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 47:719-726, 2003.
44. Kerns R, M Rybak, **G Kaatz**, F Vaka, R Cha, R Grucz, V Diwadker, and T Ward: Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of *Staphylococcus aureus*. *Bioorg Med Chem Lett* 13:1745-1749, 2003.
45. Kerns R, M Rybak, **G Kaatz**, F Vaka, R Cha, R Grucz, and V. Diwadker: Structural features of piperazinyl-linked fluoroquinolone dimers required for activity against drug-resistant strains of *Staphylococcus aureus*. *Bioorg Med Chem Lett* 13:2109-2112, 2003.
46. Allen G, **G Kaatz**, and M Rybak: Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against *Streptococcus pneumoniae* in an in vitro pharmacodynamic model. *Antimicrob Agents Chemother* 47:2606-2614, 2003.
47. **Kaatz G**, V Moudgal, S Seo, J Bondo Hansen, and J Kristiansen: Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in *Staphylococcus aureus*. *Int J Antimicrob Agents* 22:254-261, 2003.
48. Stein G, S Schooley, and **G Kaatz**: Serum bactericidal activity of the methoxyfluoroquinolones gatifloxacin and moxifloxacin against clinical isolates of *Staphylococcus* species: are the susceptibility breakpoints too high? *Clin Infect Dis* 37:1392-1395, 2003.
49. **Zloh M, G Kaatz, and S Gibbons**: Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates. *Bioorg Med Chem Lett* 14:881-885, 2004.
49. **Wei P, G Kaatz, and R Kerns**: Structural differences between paroxetine and femoxetine responsible for differential inhibition of *Staphylococcus aureus* efflux pumps. *Bioorg Med Chem Lett* 14:3093-3097, 2004.
50. **Allen G, G Kaatz, and M Rybak**: In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against *Staphylococcus aureus* in a pharmacodynamic model. *Int J Antimicrob Agents* 24:150-160, 2004.
51. **Kaatz G, and S Seo**: Effect of substrate exposure and other growth condition manipulations on *norA* expression. *J Antimicrob Chemother* 54:364-369, 2004.
52. **Gibbons S, E. Moser, and G Kaatz**: Catechin gallates inhibit multidrug resistance (MDR) in *Staphylococcus aureus*. *Planta Med* 70:1240-1242, 2004.
53. **Oluwatuyi M, G Kaatz, and S Gibbons**: Antibacterial and resistance modifying activity of *Rosmarinus officinalis*. *Phytochemistry* 65:3249-3254, 2004.

54. Kaatz G, R Thyagarajan, and S Seo: The effect of promoter region mutations and *mgrA* overexpression on transcription of *norA*, which encodes a *Staphylococcus aureus* multidrug efflux transporter. *Antimicrob Agents Chemother* 49:161-169, 2005.
55. Rybak M, R Cha, C Cheung, and G Kaatz: Clinical isolates of *Staphylococcus aureus* from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. *Diagn Microbiol Infect Dis* 51:119-125, 2005.
56. Kaatz G, F McAleese, and S Seo: Multidrug resistance in *Staphylococcus aureus* due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. *Antimicrob Agents Chemother* 49:1857-1864, 2005.
57. Pereda-Miranda R, G Kaatz, and S Gibbons: Polyacylated oligosaccharides from medicinal Mexican Morning Glory species as antibacterials and inhibitors of multidrug resistance in *Staphylococcus aureus*. *J Nat Prod* 69:406-409, 2006.
58. Kaatz G, C DeMarco, and S Seo: MepR, a repressor of the *Staphylococcus aureus* MATE-family multidrug efflux pump MepA, is a substrate-responsive regulatory protein. *Antimicrob Agents Chemother* 50:1276-1281, 2006.
59. Kaatz G, T Lundstrom, and S Seo: Mechanisms of daptomycin resistance in *Staphylococcus aureus*. *Int J Antimicrob Agents* 28:280-287, 2006.
60. Davis S, M Rybak, M Amjad, G Kaatz, and P McKinnon: Characteristics of patients with healthcare-associated SCCmec-IV methicillin-resistant *Staphylococcus aureus*. *Infect Control Hosp Epidemiol* 27:1025-1031, 2006.

Book Chapters

1. Tsuji B, G Kaatz, and M Rybak. *In* V Yu, G Edwards, P. McKinnon, C Peloquin, and G Morse (eds.), *Antimicrobial Therapy and Vaccines, Volume II: Antimicrobial Agents*. Lippincott, Williams, Wilkins, Baltimore (2005). Linezolid and Other Oxazolidinones, p. 223-242.
2. Kaatz G. *In* D White, M Alekshun, and P McDermott (eds.), *Frontiers in Antibiotic Resistance: A Tribute to Stuart B. Levy*. American Society for Microbiology, Washington, D. C. (2005). Role of Multidrug Efflux Pumps in Gram-Positive Bacteria, p. 275-285.

Review Articles

1. Kaatz G, and M Rybak: Oxazolidinones: new players in the battle against multiply resistant gram-positive bacteria. *Emerg. Drugs* 6:43-55, 2001.
2. Kaatz G: Inhibition of bacterial efflux pumps: a new strategy to combat increasing antimicrobial agent resistance. *Exp. Opin. Emerg. Drugs* 7:223-233, 2002.
3. Kaatz G: Bacterial efflux pump inhibition: a potential means to recover clinically relevant activity of substrate antimicrobial agents. *Curr. Opin. Invest. Drugs* 6:191-198, 2005.

Case Reports

1. Cabinian A, and G Kaatz: Successful therapy of *Pseudomonas aeruginosa* endocarditis with ceftazidime and tobramycin. *Am J Med* 83:366-67, 1987.

PUBLISHED ABSTRACTS (last 5 years only)

1. **Kaatz G**, V Moudgal, and S Seo: Multidrug efflux phenotype in *Staphylococcus aureus* conferred by a pump recognizing organic cations and C8-methoxy fluoroquinolones. ICAAC 42:C1-425, 2002.
2. **Kaatz G**, V Moudgal, S Seo, and J Kristiansen: Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in *Staphylococcus aureus*. ICAAC 42:C1-426, 2002.
3. Rybak M, R Cha, and **G Kaatz**: Clinical strains of *Staphylococcus aureus* from 1987 and 1989 with reduced glycopeptide susceptibility resulting from teicoplanin exposure. ICAAC 42:A-1268, 2002.
4. Rybak M, T Lodise, R Cha, P McKinnon, and **G Kaatz**: Community-acquired methicillin-resistant *Staphylococcus aureus* in an urban teaching hospital. IDSA 40:123, 2002.
5. **Kaatz G**, and S Seo: Effect of substrate exposure and environmental factors on expression of *norA* in *Staphylococcus aureus*. ICAAC 43:C1-2068, 2003.
6. **Kaatz G**, V Moudgal, and S Seo: Discovery and analysis of a *Staphylococcus epidermidis* NorA homologue. ICAAC 43:C1-2069, 2003.
7. **McAleese F, Seo S, Projan S, Bradford P, and G Kaatz**: Multidrug resistance in *Staphylococcus aureus* due to overexpression of a novel MATE-type efflux pump. ASM 104:A-105, 2004.
8. Rybak M, T Lodise, P McKinnon, E Williams, M Amjad, and **G Kaatz**: Epidemiology of community-associated methicillin resistant *Staphylococcus aureus* with Staphylococcal Cassette Chromosome Mec (SCCmec) type IV at an urban teaching hospital. IDSA 42:482, 2004.
9. **Kaatz G**, R Thyagarajan, and S Seo: Effect of promoter-region mutations and *mgrA* overexpression on *norA* expression in *Staphylococcus aureus*. ICAAC 44:C1-1186, 2004.
10. Rybak M, K Tedesco, M Amjad, R Mobarak, and **G Kaatz**: Identification of community-associated methicillin resistant *Staphylococcus aureus* by clinical and molecular methods in a large urban medical center in Detroit, MI. ICAAC 44:C2-2006, 2004.
11. **Kaatz G, C DeMarco, R Thyagarajan, V Moudgal, and S Seo**: Functional analyses of the NorA multidrug efflux pump and MgrA global regulatory protein homologues in *Staphylococcus epidermidis*. ICAAC 45:C1-1349, 2005.
12. **DeMarco C, J Schuman, S Seo, R Brennan, and G Kaatz**: Substrate exposure affects the expression of *mepA* and *mepR*, which encode a novel *Staphylococcus aureus* MATE-family multidrug efflux pump and its repressor. ICAAC 45:C1-2217, 2005.
13. **Rose W, M Rybak, and G Kaatz**: Evaluation of daptomycin treatment of *Staphylococcus aureus* endocarditis: an in vitro and in vivo simulation using historical and current dosing guidelines. ICAAC 46:A-0630, 2006.

PUBLISHED ABSTRACTS (continued)

14. **Demarco C, L Cushing, S Seo, and G Kaatz: Efflux-related drug resistance is common in clinical isolates of *Staphylococcus aureus*. ICAAC 46:C2-1146, 2006.**

PRESENTATIONS

International meetings/seminars

1. "Emergence of Resistance to Quinolone Antibiotics." Invited lecture, Fifth Annual Congress of the Inter-American Society for Chemotherapy, Buenos Aires, Argentina; November 1988.
2. "Clinical Utility of Vancomycin in the United States." Invited lecture, First Joint US-Japan Vancomycin Forum, Tokyo and Osaka, Japan; July 1994.
3. "Fluoroquinolone Resistance: Mechanisms and Implications." Invited lecture given during the symposium "Antimicrobial Resistance." 4th Western Pacific Congress on Chemotherapy and Infectious Diseases, Manila, Philippines; December 1994.
4. "Clinical Relevance of Fluoroquinolone Resistance." Invited lecture, Philippines General Hospital, Manila, Philippines; December 1994.
5. "Efflux-mediated Multidrug Resistance in *Staphylococcus aureus*." Invited lecture, Moyne Institute of Preventive Medicine, Department of Microbiology, Trinity College, Dublin, Ireland; January 1997.
6. "Teicoplanin and Vancomycin: Clinical Efficacy and Resistance." Invited lecture, Third Joint US-Japan Vancomycin Forum, Tokyo and Osaka, Japan; March 1997.
7. "Multidrug Transporters in *Staphylococcus aureus*." Invited lecture, 22nd ICC Meeting, Amsterdam, Netherlands; July 2001.
8. "Psychotropic compounds inhibit multidrug efflux pump activity in *Staphylococcus aureus*." Invited lecture, Cost Action B16 Reversal of Antibiotic Resistance by Inhibition of Transmembrane Transport Conference, Sonderborg, Denmark; November 2003.
9. "Psychotropic compounds inhibit multidrug efflux pump activity in *Staphylococcus aureus*." Invited lecture, Statens Serum Institut, Copenhagen, Denmark; December, 2003.
10. **"Inhibition of Multidrug Efflux Pumps in *Staphylococcus aureus* by Neuroleptic and Antidepressant Agents." Invited lecture, 7th European Congress of Chemotherapy and Infection, Florence, Italy; October 2005.**

PRESENTATIONS (continued)

National meetings/seminars

1. "Antimicrobial Resistance." Invited lecture, Medical Center of Delaware, Wilmington, DE; January 1991.
2. "An Animal Model of Endocarditis." Quinolone Investigator's Meeting, Napa, CA; April 1991.
3. "Enterococcal infections." Invited lecture given during the course "Update on Gram-Positive Infections", New Orleans, LA; December 1991.
4. "Daptomycin resistance in *Staphylococcus aureus*." Invited seminar, Eli Lilly and Company, Indianapolis, IN; January 1992.
5. "Quinolone Resistance In Vivo and In Vitro." Invited lecture, Albany Medical College, Albany, NY; October 1992.
6. "Fluoroquinolone Resistance in *Staphylococcus aureus*." Invited lecture given during the course "Beta-Lactam Antibiotic Resistant Gram Positive Microbes: The Present Problem and Future Directions", Naples, FL; November 1992.
7. "Genetic Mechanisms of Fluoroquinolone Resistance." Invited seminar, St. Paul-Ramsey Medical Center, St. Paul, MN; December 1993.
8. "Fluoroquinolone Use and the Incidence of Emergence of MRSA." Invited seminar, Ortho-McNeil Pharmaceuticals Anti-Infectives Scientific Liaison Mid Year Meeting, San Antonio, TX; May 2001.
9. "Efflux-Related Resistance: What Is It and Why Should I Care?" Invited seminar, American Association of Clinical Pharmacy Spring Practice and Research Forum, Savannah, GA; April 2002.

Local meetings/seminars (last 5 years only)

1. "Efflux-Mediated Multidrug Resistance in *Staphylococcus aureus*." Research presentation, Department of Internal Medicine, Division of Infectious Diseases, Wayne State University, Detroit, MI; January 2002.
2. "Efflux-Mediated Multidrug Resistance in *Staphylococcus aureus*." Invited seminar, Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI; January 2002.
3. "Efflux-Related Resistance: What Is It and Why Should I Care?" Infectious Diseases Didactic Lecture, Wayne State University School of Medicine, Detroit, MI; March 2002.
4. "Efflux-Mediated Multidrug Resistance in *Staphylococcus aureus*." Invited seminar, Department of Microbiology and Immunology, Wayne State University, Detroit, MI; April 2002.
5. "Vancomycin Resistance in *Staphylococcus aureus*." Invited seminar, ICAAC Update Conference, Detroit, MI; November 2002.

PRESENTATIONS (continued)

Local meetings/seminars (continued)

6. "Factors Influencing Expression of a Multidrug Efflux Pump Gene in *Staphylococcus aureus*." Research presentation, Research Division, John D. Dingell VA Medical Center, Detroit, MI; March 2003.
7. "Common Infectious Diseases Problems: Approach to Treatment and the Impact of Antimicrobial Agent Resistance." Invited seminar, Department of Medicine, Division of Geriatrics, St. Joseph Mercy Hospital, Ann Arbor, MI; April 2003.
8. "Antimicrobial Agent Resistance." Invited seminar, University of Michigan School of Public Health, Ann Arbor, MI; July 2003.
9. **"Bacterial Endocarditis." Resident lecture series, Wayne State University School of Medicine, Detroit, MI; December 2004.**
10. **"MepR, a Repressor of Expression of a *S. aureus* MATE-Family MDR Pump, is a Substrate-Binding Regulatory Protein." Invited seminar, Department of Biochemistry and Molecular Biology, Wayne State University, Detroit, MI; September 2005.**
11. **"Infective Endocarditis." Resident lecture series, Wayne State University School of Medicine, Detroit, MI; May 2006.**
12. **"Staphylococcal Infections." Infectious Diseases Didactic Lecture, Wayne State University School of Medicine, Detroit, MI; September 2006.**
13. **"Staphylococcal Infections." Seminars in Medicine series, JD Dingell VA Medical Center, Detroit, MI; September 2006.**